Rare Reach

Bionews has spent over a decade building the largest online network of rare disease communities, reaching an astounding average of 72% of the domestic diagnosed patient population*. Our scale within niche rare disease audiences offers pharmaceutical partners unparalleled access to engaged, highly targeted patients.

*Avg. monthly domestic reach across top 20 rare disease communities

Rare Audience Quality

Bionews is the #1 online source for rare disease news and community. Our condition-specific communities are trusted destinations for patients and caregivers who are actively researching their diagnosis, exploring treatment options, and seeking peer support.

This intent-driven engagement creates a uniquely qualified audience—deeply informed, highly motivated, and ready to act. For pharmaceutical partners, this means your message reaches patients at precisely the moment they’re making decisions that matter.

*Source: Crossix 2024

Rare Engagement

What sets Bionews apart is the authenticity and trust we’ve earned within our 50+ rare disease communities over the past decade. Our communities are safe, condition-specific spaces where patients come to seek credible clinical information and make informed treatment decisions. This high-intent, research-driven mindset fuels the strongest engagement in the industry—and delivers real impact for our pharmaceutical partners.

Partner Solutions

At Bionews, we offer a suite of strategic solutions designed to help our partners connect meaningfully with rare disease patients and caregivers. Whether you’re looking to raise brand awareness, gather deep patient insights, support clinical trial enrollment, or collaborate with advocacy organizations, our patient vetted solutions and engaged communities provide the foundation for impactful engagement at every stage of a therapy’s lifecycle.

What Our Clients Say